CD6 and neoplasm: (96) observed that IL-6 impaired anti-tumor immunity by suppressing TNF- and IFN-expression on tumor-infiltrating CD6 cells after the co-treatment of HCC with IL-6 inhibition and anti-PD-L1 checkpoint inhibitors.